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EDITORIAL
HPV-FASTER: Combined strategies
of HPV vaccination and HPV screening 
towards a one visit for cervical cancer 
preventive campaigns
HPV screening and vaccination are complementary preventive options often implemented as separate 
and non-coordinated public health programs. The HPV-
FASTER protocols aim to address this disconnect by 
combining both strategies with the ultimate purpose of 
accelerating the reduction of cervical cancer incidence 
and mortality and making the programs both cost-
effective and sustainable.
 Results from two phase III trials comparing HPV 
vaccination against placebo among adult women (aged 
up to 45 years and 55 years for 4vHPV and 2vHPV vac-
cines, respectively)1,2 showing high protection against 
HPV type specific infections and persistent infections 
and the excellent and consistent results of the HPV-
screening trials3-5 provide the basis for the HPV-FASTER 
proposal. The recognition of indications to vaccinate 
adult women in Europe6-8 and the US9 which do not 
include an upper age limit, favor the exploration of 
combined protocols of screening and vaccination and 
broadening the vaccine indications in developed and 
developing countries.
HPV vaccination trials in adult women
Evidence from epidemiological studies confirms that the 
risk of HPV infections persist as long as the individual is 
sexually active, albeit the risk of novel infections reduces 
with age in parallel with the reduction of new sexual 
partners.10 More recent cohort studies suggest that the 
risk of progression after HPV infection is constant irre-
spective of the age at infection.11 HPV vaccination trials 
in adult women confirmed the efficacy and safety of the 
vaccination. In such trials, the study groups include a 
fair proportion of HPV positive individuals and the 
observed protection is limited to the HPV types not 
prevalent at the time of vaccination. Therefore, HPV 
positive individuals will require a closer follow up 
and eventual treatment of any precancerous lesions. 
However, these women acquire long term protection 
against future HPV infections with the types included 
in the vaccine.
 In the adult women’s trials, two broad groups of 
women can be identified. The first group comprised 
women who entered the ‘per-protocol’ or ‘according-to-
protocol’ analyses of vaccine efficacy. These are typically 
defined as those who at study entry were: i) HPV16/18-
DNA negative in cervical samples and serologically 
negative for HPV16/18 antibodies (an indirect marker of 
past infections); ii) had normal or only low-grade cervi-
cal cytology abnormalities at baseline and at month 7 
after the completion of the vaccination protocol, and iii) 
received the three required vaccine doses at the specified 
timing of day one, one or two months, and six months 
without protocol violations. The second group included 
all women in the ‘intention-to-treat’ or ‘total-vaccinated-
cohort’ protocols who received at least one dose of 
the HPV vaccine, irrespective of HPV status in serum 
or by cytology at study entry or at the completion of 
the vaccination scheme. Trials of both the 4vHPV and 
2vHPV vaccines confirmed that protection against infec-
tions—and their related outcomes (cervical pre-cancer 
or cancer)—caused by vaccine-related HPV types was 
very high, provided that the women were HPV-DNA 
negative for the vaccine type at the time of vaccination; 
estimates of vaccine efficacy in the per-protocol groups 
were in the range of 85 to 90%, depending on the trial 
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women who test positive for HPV at the time of vac-
cination, the lifetime cervical cancer risk of individuals 
identified as HPV –negative and HPV vaccinated with 
a broad spectrum vaccine should be very low, tending 
to zero. Further screening requirements of these women 
would consequently be reduced to one or two lifetime 
screening events.
 Because the sensitivity of HPV tests for cervical 
intraepithelial neoplasia of grade 2 or higher (CIN2+) 
is not 100%, around 5 to 10% of the HPV-DNA-positive 
women will be misclassified as HPV negative and will 
not benefit from early diagnosis and treatment, and 
perhaps a second screening event may be necessary 
in the populations that can cope with the logistics of 
organizing it successfully.
 A major benefit from the HPV FASTER protocols 
is that the predicted subsequent needs for screening 
may be dramatically reduced to one/two lifetime visits, 
thus increasing sustainability and compliance as well 
as alleviation of the burden and workload at the health 
centers, typically overloaded already with patient care.
 If vaccination programs include also boys and 
young males –say to age 26-, the global impact is likely 
to be accelerated by enhancing herd protection and 
increasing the resilience of the vaccination program 
to temporary vaccination failures. HPV vaccines have 
shown a strong herd protection effect,15 which at least in 
part, could be attributed to a reduction of the transmis-
sion rates of HPV- positive women receiving vaccina-
tion. Cost effectiveness of these vaccination protocols 
end points.1,2 Reduced, but nonetheless important, vac-
cine efficacies of approximately 50% were calculated 
for the intention-to-treat cohorts.1,2 HPV-DNA-positive 
women did not show any evidence of protection against 
diseases related to HPV types that they tested positive 
for at the time of vaccination.12 Thus, vaccination can 
offer protection to women without a current infection 
or disease, irrespective of previous viral exposure, and 
among those currently infected, can protect against fur-
ther infections as well as re-infection with the same HPV 
type. Importantly, no safety concerns were reported for 
women that were HPV positive and received three doses 
of HPV vaccine13 or in women inadvertently vaccinated 
in the first months of pregnancy.14 Similar trials are in 
advanced stage or completion using the nine valent 
vaccine.
The HPV FASTER concept
In accordance with these findings, the proposal of the 
HPV-FASTER protocol is to offer HPV vaccination to 
women in a broad age range of 9 to 45 years irrespec-
tive of HPV-infection status. Women of any age above 
25/30 years would, in addition to the vaccination, be 
screened using a validated HPV test as part of their 
initial visit; women who test HPV-positive would be of-
fered triage and follow-up diagnostic tests and treatment 
in accordance with recommended guidelines.
 Figure 1 provides a schematic representation of 
the HPV-FASTER concept. With adequate follow up of 
Figure 1. The hPV-FASTer STrATegy ProPoSeS To 1) conTinue The generAlized VAccinATion cAmPAign 
oF The 9 To 14 yeArS old; 2) exPAnd The cATch-uP VAccinATion To AT leAST Age 25 To 30 And 3) oFFer 
hPV VAccinATion To women Aged 30 To 45 yeArS (exAcT cuToFF AgeS To be deTermined). in AddiTion, 
Any women AT The AgeS 25 To 30 And AboVe will be oFFered hPV Screening TeST wiTh concurrenT 
Follow uP (TriAge And diAgnoSTicS) oF The hPV PoSiTiVe women And iF required, TreATmenT oF The 
Pre-neoPlASTic leSionS
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need to be calibrate to the country and be attentive of 
the vaccine costs. Adding boys and young males into 
the generalized vaccination scheme has thus the po-
tential to accelerate disease control/elimination while 
protecting males from HPV induced gender specific 
malignancies even if they leave the female vaccinated 
herd protection.
 The first controlled trial under way is now ongoing 
in Mexico, where women undergoing HPV screening are 
offered HPV vaccination in a comparative trial mode. 
The study is intended to prove the safety of expanding 
the screening intervals to 10 + years endpoint. Inter-
mediate endpoints will document the added value of 
including vaccination in the screening protocol by as-
sessing the impact on HPV infection, persistent infection 
and CIN lesions.16
 The best data available from population studies in 
adult women that would resemble the HPV-FASTER 
proposal are the results of the vaccination program in 
Australia that included women up to 26 years of age 
with an average vaccination coverage close to 65%, fol-
lowed by a switching of the screening program to an 
HPV based primary screening alternative. Long term 
follow up of these gigantic national cohorts is expected 
to show that the incidence of CIN2+ and of cervical can-
cer in these populations is extremely low and therefore 
that requirements for further screening may be reduced 
to perhaps a second additional HPV screening round 
within a decade and at around menopause to handle 
the few HPV positive women that may have escaped 
detection at the time of their first screen (<5%) and the 
cases to be due to HPV types not included in the broad 
spectrum vaccine.
 One of the controversial issues for the HPV-FASTER 
strategy is whether to vaccinate women irrespective of 
HPV status or to restrict vaccination to only those who 
are HPV-DNA/ mRNA negative. This is because current 
HPV vaccines lack therapeutic effect against the devel-
opment of cervical lesions in woman who are already 
HPV-positive at the time of vaccination.12 In favor of 
the nonselective approach, the evidence indicates that: 
1) vaccination of HPV-positive women or those with 
CIN2+ is safe; 2) vaccination does not interfere with 
the treatment or follow-up of CIN2+ cases; 3) it would 
be simpler logistically, and would facilitate compliance 
with three-dose vaccination regimes if the initial vaccine 
dose is delivered in combination with an HPV test in 
women aged ≥30 years; and 4) vaccination would offer 
protection against infection and future disease caused by 
the other HPV types included in the vaccine that are not 
associated with the prevalent infection/lesion. Further 
interest in vaccinating HPV-positive adult women (in-
cluding women with a history of CIN2/3) comes from 
evidence that these women are at high lifetime risk of 
subsequent additional HPV related cancers of the ano-
genital tract and the oropharynx.17,18
The potential impact of a one-dose 
vaccination protocols
Finally, an interesting concept still poorly explored, 
hypothesized that vaccination of middle aged and 
young adult women offers the potential to boost the 
global impact of the vaccination program by reinforc-
ing the herd protection effect.19 Under this hypothesis, 
the presence of HPV antibodies in the cervical-vaginal 
fluid may result in the shedding of virions already 
coated with antibodies, thus with a potentially reduced 
capacity to infect novel sexual partners. Typically HPV 
positive women with normal cytology identified at 
screening are invited to more frequent follow up visits 
and 6 to 12 month observation period are common in 
screening protocols and guidelines.20 However, in the 
absence of any effective treatment, these observational 
time intervals create an opportunity in which transmis-
sion is likely to occur thus contributing to increase the 
global risk of infection of the population. This novel 
frame of understanding requires close verification and 
some studies are ongoing to this respect before a formal 
recommendation to vaccinate HPV positive women 
(with or without cervical lesions) can be incorporated 
as part of the routine screening programs.
 Much interest is now devoted to exploring if one 
dose of HPV vaccine would ensure long term protec-
tion against HPV infection and subsequent cancer. Such 
opportunity has been suggested by indirect evidence 
from clinical trials in which partially vaccinated girls 
and young women were followed up for antibody con-
centrations in serum and subsequent cervical lesions. In 
such observations, women receiving one dose showed 
significant protection after seven years of follow up.21,22 
Should this information be confirmed in the ongoing 
formal trials, reduction of the vaccination indication to 
one dose would greatly facilitate the logistics and increase 
the vaccination coverage. Likewise, further work will be 
worth doing to verify if the one dose regime would also 
be applicable to women above 25 and to adult women in 
screening ages thus approaching the objective of interven-
tion campaigns in which one visit could be recommended 
including HPV screen/treat and vaccination.23
 
Conclusion
In most developing countries, changing the paradigm of 
cervical cancer prevention from a strategy of repeated 
screening visits and triage/treatment of the pre-neoplas-
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tic lesions to a campaign-type strategy tending to a one 
lifetime visit that includes screen/treat and vaccinate is 
an important alternative.
 In developed countries, where screening is largely 
integrated into the health services, the option to receive 
vaccination against a significant reduction of the screen-
ing requirements is likely to be discussed as a right to 
know of the opportunities for prevention available to 
women. Under this frame, the health system is required 
to provide unbiased information to women for an in-
formed option of receiving or not the HPV vaccine. The 
public health systems in developed countries need to 
understand that the integration of screening protocols 
with the vaccination campaigns is necessary and highly 
desirable. In practical term, this is already occurring 
when vaccinated cohorts are massively entering the 
screening ages.
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